Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia‐associated immunophenotypes

Olaru, Daniela; Campos, Lydia; Flandrin, Pascale; Nadal, Nathalie; Duval, Amélie; Chautard, S.; Guyotat, Denis

doi:10.1002/cyto.b.20371

Cited by 33 publications

(30 citation statements)

References 40 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The progeny of LSCs -AML blasts are due to their arrest in maturation and differentiation phenotypically partially similar to normal granulocyte progenitors, but they often possess imunophenotype abnormalities not typical for normal myeloid development. Multiple studies have been done to assess phenotypic abnormalities in AML blasts (leukemia-associated immunophenotypes, LAPs) which are totally absent or present at very low levels in normal bone marrow and bone marrow recovering from induction or consolidation chemotherapy [84,85]. LAPs include expression of markers not normally expressed on myeloid cells, asynchronous coexpression of markers normally expressed at different stages of maturation as well as overexpression or underexpression of myeloid markers [86].…”

Section: Cd96mentioning

confidence: 99%

Immunophenotype characterization of hematopoietic stem cells, progenitor cells restricted to myeloid lineage and their leukemia counterparts

Fajtova¹,

Babušíková²

2010

neo

View full text Add to dashboard Cite

The aim of this review is to evaluate recent immunophenotype knowledge of hematopoietic stem cells and their restricted progenies committed to myeloid lineage -common myeloid progenitors, myelo-monocytic progenitors, megakaryo-erythroid progenitors and granulocyte progenitors up to mature neutrophil granulocyte. This study evaluates also recent knowledge of immunophenotype of leukemic stem cells and their more differentiated progeny committed to myeloid lineage -acute myeloid leukemia blast cells with regard to their phenotypic similarity to normal stem and granulocyte committed progenitor cells. Improved knowledge of normal stem and progenitor cells phenotypes, identifying new leukemia-specific markers, searching for aberrant marker expression and evaluation of aberrant intensity or combination of various marker expressions is important for distinguishing normal cells from their malignant counterpart in view of the diagnostics of leukemias or follow-up of minimal residual disease.

show abstract

Section: Cd96mentioning

confidence: 99%

Immunophenotype characterization of hematopoietic stem cells, progenitor cells restricted to myeloid lineage and their leukemia counterparts

Fajtova¹,

Babušíková²

2010

neo

View full text Add to dashboard Cite

show abstract

“…Flow cytometric MRD detection in both ALL and AML often depends on the persistence of cells with a particular leukemia-associated immunophenotype identified at the time of diagnosis. [305][306][307][308] Even when flow cytometry methods that depend on recognizing differences between normal and abnormal cells are used, 309,310 it is advantageous to be able to compare initial and posttreatment phenotypes because those often change in predictable ways. Molecular methods of detecting MRD in both ALL and AML require that leukemic cells be characterized and sequenced at diagnosis, whether MRD detection is performed by conventional PCRbased techniques [311][312][313] or by NGS.…”

mentioning

confidence: 99%

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology

Arber¹,

Borowitz²,

Cessna³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

100

View full text Add to dashboard Cite

Context.-A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyotype analysis, and often, molecular genetic testing. Although many aspects of the workup for acute leukemia are well accepted, few guidelines have addressed the different aspects of the diagnostic evaluation of samples from patients suspected to have acute leukemia.Objective.-To develop a guideline for treating physicians and pathologists involved in the diagnostic and prognostic evaluation of new acute leukemia samples, including acute lymphoblastic leukemia, acute myeloid leukemia, and acute leukemias of ambiguous lineage.Design.-The College of American Pathologists and the American Society of Hematology convened a panel of experts in hematology and hematopathology to develop recommendations. A systematic evidence review was conducted to address 6 key questions. Recommendations were derived from strength of evidence, feedback received during the public comment period, and expert panel consensus.Results.-Twenty-seven guideline statements were established, which ranged from recommendations on what clinical and laboratory information should be available as part of the diagnostic and prognostic evaluation of acute leukemia samples to what types of testing should be performed routinely, with recommendations on where such testing should be performed and how the results should be reported.Conclusions.-The guideline provides a framework for the multiple steps, including laboratory testing, in the evaluation of acute leukemia samples. Some aspects of the guideline, especially molecular genetic testing in acute leukemia, are rapidly changing with new supportive literature, which will require on-going updates for the guideline to remain relevant.

show abstract

“…Often, depending on the expertise of the operator, specific cell populations-particularly those present at low frequencies-can be misidentified. Overestimation and/or underestimation of specific minor cell populations has a direct impact on the assessment of MRD with potential clinical/diagnostic consequences (5,7,28). More recently, we have described an alternative, automated method for analysis of flow cytometry immunophenotypic data (22,25).…”

mentioning

confidence: 99%

“…However, it should be highlighted that for MRD investigation by flow cytometry, an expert operator with extensive and detailed knowledge about the patterns of protein expression associated with normal versus neoplastic B-cells is typically required for adequate data analysis (1,5,11,28). This, together with the variable patterns of phenotypic aberrations detected among different subtypes of B-CLPD has limited the establishment and implementation of standardized data analysis procedures that would facilitate the extended use of standardized flow cytometry MRD approaches in routine clinical diagnostic laboratories.…”

mentioning

confidence: 99%

“…In line with this, the proposed probabilistic approach could also be useful in the evaluation of MRD in other hematological malignancies. This would be particularly useful in acute myeloid leukemias where manual data analysis is much more complex due to coexistence of different abnormal cell populations in the same sample and a marked phenotypic heterogeneity (6,28) and to the effects of therapy (43).…”

mentioning

confidence: 99%

See 1 more Smart Citation

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B‐cell chronic lymphoproliferative disorders

et al. 2008

View full text Add to dashboard Cite

Multiparameter flow cytometry has become an essential tool for monitoring response to therapy in hematological malignancies, including B-cell chronic lymphoproliferative disorders (B-CLPD). However, depending on the expertise of the operator minimal residual disease (MRD) can be misidentified, given that data analysis is based on the definition of expert-based bidimensional plots, where an operator selects the subpopulations of interest. Here, we propose and evaluate a probabilistic approach based on pattern classification tools and the Bayes theorem, for automated analysis of flow cytometry data from a group of 50 B-CLPD versus normal peripheral blood B-cells under MRD conditions, with the aim of reducing operator-associated subjectivity. The proposed approach provided a tool for MRD detection in B-CLPD by flow cytometry with a sensitivity of 8 3 10 25

show abstract

Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia‐associated immunophenotypes

Cited by 33 publications

References 40 publications

Immunophenotype characterization of hematopoietic stem cells, progenitor cells restricted to myeloid lineage and their leukemia counterparts

Immunophenotype characterization of hematopoietic stem cells, progenitor cells restricted to myeloid lineage and their leukemia counterparts

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B‐cell chronic lymphoproliferative disorders

Contact Info

Product

Resources

About